ALPHA (TNFa) IN OBESITY



Similar documents
Diabetes and Obesity. The diabesity epidemic

Introduction. Pathogenesis of type 2 diabetes

Body Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME

Diabetes mellitus. Lecture Outline

Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007

SDS gel electrophoresis was performed using a 4% by 20% gradient gel 8. Quantification of Western blots was performed using Image J Processing and

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME

Insulin Receptor Substrate 1 (IRS1) Gene Variation Modifies Insulin Resistance Response to Weight-loss Diets in A Two-year Randomized Trial

DIABETES AND INSULIN RESISTANCE DIABETES PREVALANCE

Is Insulin Effecting Your Weight Loss and Your Health?

Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075

Summary and conclusions. Chapter 8. Summary and conclusions

GLUCOSE HOMEOSTASIS-II: An Overview

Give a NOD to diabetes:

Calculating and Graphing Glucose, Insulin, and GFR HASPI Medical Biology Activity 19c

PowerPoint Lecture Outlines prepared by Dr. Lana Zinger, QCC CUNY. 12a. FOCUS ON Your Risk for Diabetes. Copyright 2011 Pearson Education, Inc.

Menopause. Weight Loss. A Special Report on Weight Gain During Menopause. contact us. FROM THE DESK OF: Carolyn J. Cederquist, M.D. Dr.

Actions of Hormones on Target Cells Page 1. Actions of Hormones on Target Cells Page 2. Goals/ What You Need to Know Goals What You Need to Know

Endocrine Responses to Resistance Exercise

Endocrine System: Practice Questions #1

Diabetes and Obesity in Children. Janie Berquist, RN, BSN, MPH, CDE Children s Mercy Hospitals and Clinics Kansas City, MO

Insulin s Effects on Testosterone, Growth Hormone and IGF I Following Resistance Training

Healthy Aging Lab: Current Research Abstracts

ETIOLOGIC CLASSIFICATION. Type I diabetes Type II diabetes

DNA Fingerprinting. Unless they are identical twins, individuals have unique DNA

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

Regulation of Metabolism. By Dr. Carmen Rexach Physiology Mt San Antonio College

Version Module guide. Preliminary document. International Master Program Cardiovascular Science University of Göttingen

Cardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011

High Blood Cholesterol

Effects of macronutrients on insulin resistance and insulin requirements

A Calorie is a Calorie Or is It? 6 th Biennial Childhood Obesity Conference, June 30, 2011

EVIDENCE THAT THE ASSOCIATION BETWEEN EXERCISE INTENSITY AND INSULIN SENSITIVITY IS SEX DEPENDENT

An Interview with Gerald Reaven: Syndrome X : The Risks of Insulin Resistance

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

The Polyphenol Study. Effect of Dietary Polyphenols on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome

GLUCOHelp. A fast-acting, clinically proven way to control blood glucose levels. Banaba Leaf Extract, Standardized to 18% Corosolic Acid

Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012

Human Clinical Study for Free Testosterone & Muscle Mass Boosting

Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?

Master of Science. Obesity and Weight Management

Family History and Diabetes. Practical Genomics for the Public Health Professional

DRUGS FOR GLUCOSE MANAGEMENT AND DIABETES

Reversing type 2 diabetes: pancreas composition and function during return to normal glucose tolerance

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Client Sex Facility Birth Date Height Weight Measured Sample Client Male (not specified) 00/00/ in lbs. 02/20/2016

How To Understand How Gene Expression Is Regulated

7 Ways Your DNA Influences Your Ability to Lose Weight

The Influence of Infant Health on Adult Chronic Disease

Diabetes and Insulin Signaling

Sweet-taste receptors, glucose absorption and insulin release: Are LCS nutritionally active?

Type 2 Diabetes and Prediabetes: A New Understanding of Cause and Treatment. Bruce Latham, M.D. Endocrine Specialists Greenville Health System

Abdulaziz Al-Subaie. Anfal Al-Shalwi

NUTRITION IN LIVER DISEASES

Diabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.

The diagram below summarizes the effects of the compounds that cells use to regulate their own metabolism.

WHAT DOES DYSMETABOLIC SYNDROME MEAN?

GT-020 Phase 1 Clinical Trial: Results of Second Cohort

What is Type 2 Diabetes?

Kansas Behavioral Health Risk Bulletin

The South Asian Indian Women s s Weight Loss Study. Latha Palaniappan, MD, MS BIRCWH Scholar October 20, 2005

High Throughput Assays for Mouse Metabolic Markers: Insulin, Leptin and Adiponectin

Describe how these hormones exert control quickly by changes in phosphorylation state of enzyme, and more slowly by changes of gene expression

Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children

Guidelines for the management of hypertension in patients with diabetes mellitus

Division of Diabetes Treatment and Prevention Advancements in Diabetes Seminar December 3, 2013

4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH

7 Answers to end-of-chapter questions

The Key to Natural Weight Management Support. Presented by Sabinsa Corporation

Cancer treatment and diabetes

Autoimmunity and immunemediated. FOCiS. Lecture outline

Investigation of the effect of isomaltulose (PalatinoseTM) on metabolic parameters in subjects with Type 2 Diabetes.

Gene Therapy. The use of DNA as a drug. Edited by Gavin Brooks. BPharm, PhD, MRPharmS (PP) Pharmaceutical Press

DIET AND EXERCISE STRATEGIES FOR WEIGHT LOSS AND WEIGHT MAINTENANCE

Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry

Freiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.

Comparison of Three Methods of Exercise on Insulin Sensitivity Index of Middle-Aged Men

Obesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and

CHAPTER V DISCUSSION. normal life provided they keep their diabetes under control. Life style modifications

Homeostatic Model Assessment (HOMA)

Metabolic syndrome a new world-wide definition. A Consensus Statement from the International Diabetes Federation

TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU

Eating, pooping, and peeing THE DIGESTIVE SYSTEM

1333 Plaza Blvd, Suite E, Central Point, OR *

Absolute cardiovascular disease risk assessment

Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc.

The CSIRO Total Wellbeing Diet -from lab bench to kitchen bench. Manny Noakes CSIRO Food and Nutritional Sciences

NASH: It is not JUST a Fatty Liver. Karen F. Murray, M.D. Director of Hepatobiliary Program Children s Hospital and Regional Medical Center

Transcription:

THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide University South Australia August 2001

TABLE OF CONTENTS 1.2.3 Types of Obesity 1.2.4 Obesity related diseases 1.2.5 Determining Obesity......5 1.2.6 Benefits of weight loss in obesity...6 1.3. Insulin resistance and type II diabetes 1.3.1 Role of Insulin.....6 1.3.2 Defining insulin resistance...,,...7 1.3.3 How insulin resistance develops into type II diabetes...8 1.3.4 Molecular defects involved in Insulin Resistance... 10 1.3.5 The Insulin Cascade... 10 1.3.6 Risk factors for developing insulin resistance.....11 1.3.6.a Disruptions to the GLUT4 glucose transport..,.,...,...12 1.3.6.b Disruptions to lipid metabolism result in insulin resistance.....13 1.4 Adipocyte metabolism......14 1.4.1 Adipose tissue mass contro1...... 14 1.4.2 Lipogenesis and Lipolysis...... 14 1.5 Tumour Necrosis Factor-alpha (TNFa).....,..,.,...17 1.5.1 TNFc gene, protein and receptors...... 17 1.5.2 TNFa in obesity and insulin resistance...19 1.5.2.t Animal studies......19 1.5.2.b Human studies......21 1.5.2.b (i) Adipose tissue and skeletal muscle expression and secretion of Tf[Fc..22 1.5.2.b (ii) Monocyte production of TI\Fc, in human obesity....,...,...24

1.5.2.b (iii) Circulating levels of TI\Fo in humans.,,...,...,..,24 1.5.3 Polymorphisms in the TNT'ø promoter....,..,..,26 1.5.4 Negative findings with TNFc neutralisation in humans......28 1.5.5 Actions of TllFcr, 29 1.5.5.a How does TNFo interfere with insulin signalling?,..,,29 1.5.5.b The action of TNFa on enzymes involved in lipid metabolism...31 1.5.5.c Apoptosis induced by TNFo...32 1.5.5.d Indirect actions of TNFa......32 1.6 TNFa Receptors...34 1.6.1 Actions of the TllFo receptors...34 1.6.2 TNFo Receptors, obesity and insulin resistance... 1.7 TNFcr interacting with other adipocyte derived factors......37 1.7.1 Interactions between TNFo and other cytokines...38 L.7.2.Actions of TllFa on leptin production...39 1.7.3 Actions of ThlFo on plasminogen activator inhibitor-l (PAI-l)...39 1.8 The action of TZDs on TNFcr.....41 L.9 Does TNFcI have a pivotal role in limiting fat mass?..,...,..42 1..10 Summary and aims of the thesis...43 Chapter 2: General Methods... I 2.1 Study Design 2.1.1 Clinical Weight Loss Studies 2.1.2 Additional Subjects......1 2.1.3 Subjects recruited for weight loss studies......3 2.1.4 Inclusion Criteria...3 2.1.5 Dietary Information for Subjects......4 2.1.6 Diet Analysis for \ileight Loss Studies......4 2.2 Study Protocol...5 2.2.1 Blood Sample Collection... 7 2,2.2 Oral Glucose Tolerance Test (OGTT)... 7 2.2.3 Weight, waist circumference and height measurements 2,2.4Blood pressure...36 2.2.5 Dual-energy X-ray absorptiometry for measuring Body Composition...8 2.3 Analysis of Blood Samples......9 2.3.1 Cobas-Bio Analysis... 9 2.3.2 Insulin radioimmunoassay...9 2.4 Peripheral Blood Mononuclear Cell (PBMC) preparation...10 7 I

2.4.1 PBMC isolation... 2.4.2 Cell Count and Incubation with TIt{Fa secretagogue......10 2.4.3 Percentage of monocytes in cell suspension... 2.5 Determining Production of TNFc from PBMC...... 11 2.6 Abdominal adipose tissue Biopsies...12 2.6.1 Biopsy procedure 2.7 RNA extraction t2 2.7.1RNA extraction. t2 2.7.2 RNA Quantitaion...13 2.8 Quantitation of TNFc mrna......13 2.8.1 Reverse Transcription......13 2.8.2 PCR Ämplification...... 14 2.8.3 Standard curve construction...... 18 2.9 Genomic DNA Extraction...... 18 2.L0 TNFo NcaI Polymorphism...19 2.lù.1Amplification of genomic DNA...19 2,10,2 PCR Conditions......20 2.10.3 RFLP Analysis...21 2.1 I Statistics... Chapter 3: In vitro production of TNFa by P8MCs...... I 3.1 Introduction...1 3.1.1 TNFo production... 3.1.2 Monocyte production of TNFø in type II diabetes.... 2 3.1.3 Monocyte production of TNFo in obesity...3 3.1.4 Monocyte production of TNFo with weight loss 3.1.5 Aim of this chapter... 3.2 Methods... J J...5 3.2.2 PBMC stimulation by LPS 6 3.2.3 ELISA kit sensitivity... 7 9 3.3.1 Diet Analysis... 3.3.2 Weight loss and diet...... 9..10 3.3.3 Metabolic differences between non-diabetics and type II diabetics...11 3.3.4 Weight loss and the effects of diabetes and gender... t2 3.3.4 Weight loss and changes in metabolic parameters......13

Variable...... L5 3.3.5 DietarA influence on TNFa production from PBMCs......15 3.3.6 Associations between TNFo production and obesity...15 3.3.7 Weight loss and TllFc production from PBMC 3.3.8 Correlations between TNFo and lipids 3.3.9 Correlations between plasma insulin and TNFo production 3.3.10 Correlations between plasma glucose and TNFo production from PBMCs...20 3.3.11 Correlations between SBP and TNFo production from P8MCS...,.,,.,.,21 3.4 Discussion... 3.4.1 Monocyte production of TNFcr in obesity and insulin resistance..,,,..22 3,4.2 The effect of obesity and weight loss on TllFo production by PBMCs... 23 3.4.3 Associations with glucose and insulin and TNFo production from P8MCs...25 3.4.4 Different factors that could potentially affect TNFc production from PBMCs..,26 3.4.5 Gender effects on TNFo production..,...,.,...,27 3.4.6 Blood Pressure and TNFo.,,,..,,.,.,.27 3.5 Critical Method Evaluation...28 3.5.1 Concentration of LPS used to stimulate PBMCs......28 3.6 Conclusion and Summary.,...,,,..,,,,29 Chapter 4: TNFcr, mrna expression in adipose tissue...1 4.1 Introduction...1 4.1.1 TNFa mrna expression in adipose tissue.1 4.1.2 Associations between TNFc mrna expression in adipose tissue and obesity...1 4.1.3 Chapter Aim......3 t6 18 19 4.2.1 Subject Characteristics 4.2.2ßat Biopsies 4.2.3 Method of RNA extraction.. 4.2.4 Quality of RNA extracted 4.2.5 Statistics... 3 4 4 f, 5 4.3.1 Diet Analysis... 4.3.2 Weight loss and diet......7 4.3.3 Changes in metabolic parameters with weight Ioss......7 4.3.4 TltlFg mrna abundance in adipose tissue...10 4.3.5 Associations between TNFcl, mrna expression and adiposity...12 4.3.6 Associations between TNFa mrna abundance and metabolic variables...15

4.4 Discussion......17 4.4.1 IIow is adipose tissue TNFc mrà[a abundance associated with obesity...17 4.4.2Yanations in TNFc mrna expression in adipose tissue between subjects...18 4.4.3.Why does weight loss alter TNFø mrna abundance in adipose tissue?...19 4.4.4 Associations between TNFø mrna and metabolic parameters...20 4.5 Critical Method Evaluation...,,,...22 4.5.1 Adipose tissue biopsies. 4.5.2 Methods of quantifying mrna 23 4.6 Summary and conclusion...25 CHAPTER 5: -308 NcoI TNFCT RFLP...... 1 5.1 Introduction... I 5.1.1 Defining polymorphisms......1 5.1.2 Function of the -308 TNFa RFLP......3 5.1.3-308 TIrlFa RFLP and obesity...3 5.1.4 Frequency of the -308 TNTo RFLP...5 5.1.5 Chapter Aims... 5 6 5.2.1. (a) Subjects involved in weight loss studies 5.2.1. (b) Subjects recruited only for RFLP analysis...7 5.2.1. (c) Subjects in whom PBMC production of TNFo was also measured..,,.,,.,,,,.,.7 5.2.1. (d) Subjects in whom TNFcr, expression in adipose tissue was also measured...8 5.2.2 Statistics and Data Analysis...10 5.3.1 Allele frequency 10 5.3.2 Baseline characteristics......,..,12 5.3.3 Allele frequency of subjects involved in weight loss trials...15 5.3.4 Diet analysis based on genotype 5.3.5 Clinical and metabolic parameters during weight Ioss... 5.3.6 Gender and diabetes status differences with weight loss... t6 17 5.3.7 Associations with genotype and weight loss...... 19 5.4.8 A.ssociations with genotype and systolic blood pressure...23 5.3.9 Differences in genotype grouping......23 5.3.10 TNFct production from PBMCs in relation to the NcoI RFLP...,,,,,24 5.3.11 TNFc expression in adipose tissue in relation to the NcoI RFLP.,,.,24

5.3.12 Changes in percent total body fat and abdominal fat based on the NcoI RFLP 25 5.4 Discussion 5.4.1 Allele frequency......26 5.4.2 Associations between -308 TNFc RFLP and obesity.,.,..,.27 5.4.3 Weight loss and -308 TNFo RFLP...,...,...29 5.4.4-308 TNFo RI'LP associations with factors influencing syndrome X...30 5.4.5-308 TNFo RI'LP and TNFcr production from PBMCs and mri\a expression.3l 5.5 Conclusion......32 Chapter 6: General Discussion......,... I 6.1 Overview......1 6.2 Summary of findings......1 6.2.1 Associations between TNFc and obesity...3 6.2.2Eow Tl[Fo responds to weight loss......3 6.2.3 Associations of TNFo production with metabolic variables...5 6.2.3.a Blood Pressure......5 6.2.3.b Lipids...77 6.2,3.c Insulin......88 6.3 Implications......100 6.3.1 What is the main source of circulating TI\IFø?......100 6.3.2 Clarifying the role of TNFcr production by different tissues......,...,..,. t22 6.3.3 TNFo and the interaction with other adipocyte derived factors... 13 6.4 Limitations and suggestions for future directions of research... 144 6.4.1 Other adipocyte derived factors...... 15 6.4.2 Other RFLPs in the TNFa gene which might be associated... 16 6 L 2 3 8.1.1 Dextran T500-60/0...,... 8.1.2 Counting Fluid for Mononuclear cell number determination... 1 I 1 8.2 Molecular Biolory Solutions...... 1 1 8.2.1 Loading Buffer recipe... 1

ABSTRACT Tumour necrosis factor-alpha (TNFø) is an inflammatory mediator and has also been described as a possible factor in obesity related insulin resistance and type II diabetes, although a clear mechanism is still to be elucidated. This thesis describes six randomised controlled dietary intervention trials that were performed in free living subjects, with the primary aim of inducing weight loss through moderate energy restrictive (-6000 KJ/day) diets of varying nutrient composition. Each study was 12 weeks in duration and all subjects involved were either overweight or obese. In all studies plasma lipids, glucose, insulin and blood pressure were measured before and after weight loss. The first study, described in Chapter 3, involved measuring the production of TNFa by stimulated peripheral blood mononuclear cells (PBMCs), before and after weight loss, in obese type II diabetics and non-diabetic controls. There was a fall in production of TNFø with weight loss and this was more pronounced in males compared with females. There was no correlation between TNFa production and any msasure of adiposity but there was a positive association between TNFc production and blood pressure. In the second study (Chapter 4), TNFa mrna expression in subcutaneous adipose tissue was me $ured using quantitative real time RT-PCR, both before and immediately after a12 week period of caloric restriction, in obese non-diabetic women. As found with monocyte production of TNFa, there was no association between baseline TNFa mrna expression and obesity but a positive association was observed with blood pressure. TNFa mrna

abundance was not altered with weight loss. There was great variation in the effect of weight loss on TNFø mrna expression, but overall there was a tendency for TNFa mrna to be elevated (p:0.06) following weight loss. The presence of a functional polymorphism (G)l) in the TNFo promoter at position -308 was determined in all of the subjects recruited for the six weight loss studies and an additional small number of obese subjects who did not undergo weight loss (Chapter 5). The TNF,4 allele in this Australian population was present at a frequency (0.21), which is comparable to other populations, but there was no difference between genotypes in initial BMI, the amount of weight lost (GG, 8.1 + 0.65k9; AG,6.9 L 0.l7kg; AA,7.6 + 0.l2kg) or any metabolic variable. In summary these studies show that the production of TNFø by PBMCs and expression by adipose tissue is not associated with obesity. Expression of TNFc in adipose tissue and monocyte production of TNFa respond differently to moderate weight loss. The association between TNFo expression and production and blood pressure is one that should be explored further. The disparate results between animal and human studies suggest that factors other than TNFo must also be involved in the metabolic changes associated with obesity.